

PICASSO: Cilostazol Versus Aspirin in Ischemic Stroke Patients With Intracerebral Hemorrhage or Multiple Microbleeds



Purpose: In ischemic stroke patients cilostazol was compared to aspirin for safety and effectiveness in prevention of future cardiovascular events.

Trial Design: 2X2 international, multicenter, randomized, controlled; N= 1534. Patients with a non-cardioembolic ischemic stroke randomized to cilostazol (100mg/twice daily) or aspirin (100mg/day). 2-year mean f/u.

Primary Endpoints: Safety and Efficacy - time to hemorrhagic stroke (safety) and composite of stroke, myocardial infarction and vascular death (efficacy)

Trial Results	aspirin	cilostazol	P value
Composite vascular events @ 2 years - efficacy	80 events	63 events	0.004
Cerebral hemorrhage - safety	18 events	9 events	0.09
Stroke	73 events	48 events	0.03
Myocardial Infarction	2 events	9 events	0.03

Conclusions: Compared to aspirin, the number of strokes were less with cilostazol, but there were more myocardial infarctions in the cilostazol group.

